文献速递消化系统肿瘤

循环肿瘤DNA作为可切除与不可切除IV期结直肠癌生物标志物的系统综述与Meta分析

Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
PubMed 文献 · Eur J Cancer · 2021-01-07

该系统综述与Meta分析纳入28项研究共2823例IV期结直肠癌患者,评估循环肿瘤DNA(ctDNA)与临床结局的相关性。Meta分析显示治疗后ctDNA可检测与总生存(HR 2.2,95%CI 1.79-2.69,p<0.00001)和无进展生存(HR 3.15,95%CI 2.10-4.73,p<0.00001)显著相关。可切除患者中ctDNA检测较影像学复发提前10个月,提示其作为预后与疗效监测标志物的潜力。

要点

  • 治疗前80%-90%的IV期结直肠癌患者可检测到ctDNA。
  • 治疗后ctDNA可检测与更短的总生存和无进展生存显著相关。
  • 可切除患者中ctDNA检测较影像学复发提前10个月。

核心结论

  • ctDNA在多数可切除与不可切除IV期结直肠癌患者中可检测到。
  • ctDNA存在与更短的总生存明确相关,其变化是 adverse 疾病行为的早期生物标志物。
  • 需要前瞻性试验验证其临床效用。

研究设计与样本

  • 系统综述与Meta分析,纳入28项研究,共2823例IV期结直肠癌患者。
  • 文献检索筛选将ctDNA测量与临床结局(影像学反应、二次切除率、PFS、DFS或OS)相关的研究。

主要发现

  • 治疗前ctDNA可检测率为80%至90%。
  • 治疗后(手术或化疗)可检测ctDNA与总生存相关(HR 2.2,95%CI 1.79-2.69,p<0.00001)。
  • 治疗后(手术或化疗)可检测ctDNA与无进展生存相关(HR 3.15,95%CI 2.10-4.73,p<0.00001)。
  • 不可切除疾病中,一个周期系统治疗后的ctDNA变化具有预后价值。
  • 可切除疾病中,ctDNA检测较影像学复发提供10个月提前量。

临床怎么用

  • ctDNA可作为IV期结直肠癌治疗分层与疗效监测的潜在生物标志物。
  • 治疗后ctDNA可检测提示预后不良,可考虑加强随访或调整治疗策略。
  • 可切除患者术后ctDNA监测可能较影像学更早发现复发。

局限性

  • 需要前瞻性试验验证ctDNA的临床效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For patients with metastatic colorectal cancer, stratification for treatment (surgery or chemotherapy) is often based on crude clinicopathological characteristics like tumour size and number of lesions. Circulating tumour DNA (ctDNA) acts as a potential biomarker of disease trajectory and biology, allowing better stratification. This study aims to systematically review ctDNA in stage IV colorectal cancer to assess its potential role as a prospective biomarker to guide management decisions. METHODS: A literature search was performed to identify studies where the measurement of ctDNA in stage IV colorectal cancer was correlated with a clinical outcome (radiological response, secondary resection rate, PFS, DFS or OS). RESULTS: Twenty-eight studies were included, reporting on 2823 patients. Circulating tumour DNA was detectable in between 80% and 90% of patients prior to treatment. Meta-analysis identified a strong correlation between detectable ctDNA after treatment (surgery or chemotherapy) and overall survival (HR 2.2, 95% CI 1.79-2.69, p < 0.00001), as well as progression-free survival (HR 3.15, 95% CI 2.10-4.73, p < 0.00001). ctDNA consistently offered an early marker of long-term prognosis in irresectable disease, with changes after one cycle of systemic therapy demonstrating prognostic value. In resectable disease treated with curative intent, detection of ctDNA offered a lead time over radiological recurrence of 10 months. CONCLUSION: Circulating tumour DNA is detectable in the majority of resectable and irresectable patients. The presence of ctDNA is clearly associated with shorter overall survival, with changes in ctDNA an early biomarker of adverse disease behaviour. Prospective trials are essential to test its clinical efficacy.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Jones RP, Pugh SA, Graham J, et al. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis. Eur J Cancer. 2021. PMID: 33422803. doi:10.1016/j.ejca.2020.11.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。